Please login to the form below

Not currently logged in
Email:
Password:

EC expands Janssen’s prostate cancer drug reach

Zytiga plus predinson/prednisolone will now treat mHSPC patients

JanssenJanssen has chalked up a significant win in the European market following a ruling on its prostate cancer drug Zytiga (abiraterone acetate), receiving the go-ahead to add an earlier stage of metastatic prostate cancer to the drug’s label.

Initially the once daily oral drug was approved in combination with predinson/prednisolone for the treatment of metastatic castration-resistance prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of ADT and in patients where chemotherapy is not yet clinically indicated.

It was also originally approved for the same indication but in patients whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

However, the European Commission’s decision has extended Zytiga’s indication to include the treatment of newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).

Dr Ivo Winiger-Candolfi, oncology solid tumour therapy area lead, Janssen EMEA, said: “This EC approval is a major step forward for men living with prostate cancer across Europe and offers patients with newly-diagnosed high-risk mHSPC a new treatment option.”

Prostate cancer is the most common form of cancer in men throughout Europe and according to the Johnson and Johnson pharma group, patients with mHSPC, particularly with high-risk characteristics, have a poor prognosis.

Dr Winiger-Candolfi added: “We are encouraged by the data we have seen to date and remain committed to transforming outcomes for prostate cancer patients.

The approval from the EU regulators follows a recommendation from the Committee for Medical Products for Human Use (CHMP), which was based on the positive results of Janssen’s LATITUDE study.

Article by
Gemma Jones

23rd November 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....
Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....